Aldeyra halts trials, focuses on ocular assets to stretch runway.

Aldeyra Therapeutics has halted clinical development of two systemic disease programs to stretch out its cash runway to the end of next year. The action is intended to enable Aldeyra keep pushing its ocular disease programs through late-phase development despite its falling cash reserves. [ABSTRACT FROM AUTHOR]